Pre-made Talacotuzumab benchmark antibody ( Whole mAb, anti-IL3RA therapeutic antibody, Anti-IL3R/CD123/IL3RX/IL3RY/hIL-3Ra Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Talacotuzumab biosimilar, Whole mAb, Anti-IL3RA Antibody: Anti-IL3R/CD123/IL3RX/IL3RY/hIL-3Ra therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

A humanized IgG1 monoclonal antibody against CD123 (Interleukin-3 receptor alpha chain or IL3RA) with potential antineoplastic activity. Upon intravenous administration, talacotuzumab binds to and neutralizes CD123.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-545-1mg	1mg	3090
GMP-Bios-ab-545-10mg	10mg	Inquiry
GMP-Bios-ab-545-100mg	100mg	Inquiry
GMP-Bios-ab-545-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Talacotuzumab biosimilar, Whole mAb, Anti-IL3RA Antibody: Anti-IL3R/CD123/IL3RX/IL3RY/hIL-3Ra therapeutic antibody
INN Name	Talacotuzumab
Target	IL3RA
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Active
100% SI Structure	4jzj:HL:AB
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2017
Year Recommended	2018
Companies	CSL;Janssen Biotech
Conditions Approved	na
Conditions Active	Myelodysplastic syndromes
Conditions Discontinued	Acute myeloid leukaemia;Systemic lupus erythematosus
Development Tech	na